GlassScriptPhysician profile
Lilly-Rose Paraskevas
NPI 1891991147
$7,402.39
in general payments reported to CMS, 2019-2025
36 companies · $2,427 in 2025
The $2,427 reported for 2025 was more than what 80% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $476 · 2020: $562 · 2021: $558 · 2022: $539 · 2023: $1,062 · 2024: $1,779 · 2025: $2,427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,096 · Education: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,095.96 |
| Education | $171.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,060.81 | 2020-2025 | |
| Janssen Biotech, INC. | $943.25 | 2020-2025 | Tremfya, Simponi, Stelara |
| Arcutis Biotherapeutics, INC. | $585.04 | 2023-2025 | Zoryve |
| Revance Therapeutics, INC. | $579.01 | 2024-2025 | Daxxify |
| Amgen INC. | $397.39 | 2023-2025 | Otezla, Otezla |
| Incyte Corporation | $382.30 | 2022-2025 | Opzelura |
| Biofrontera INC. | $312.30 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Dermira, INC. | $279.24 | 2019-2021 | |
| Galderma Laboratories, L.P. | $275.21 | 2020-2025 | Nemluvio |
| Botanix Sb INC | $257.26 | 2025 | Sofdra |
| Abbvie INC. | $249.96 | 2019-2025 | |
| Leo Pharma INC. | $201.43 | 2024-2025 | Adbry, Anzupgo |
| Pfizer INC. | $193.67 | 2019-2023 | |
| Dermavant Sciences, INC. | $187.98 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $168.05 | 2020-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $161.91 | 2022-2025 | Taltz, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $161.79 | 2019-2025 | Dupixent, Libtayo |
| Merz North America, INC. | $102.85 | 2020-2023 | Xeomin |
| Ucb, INC. | $102.01 | 2021-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $91.86 | 2021-2023 | Winlevi, Absorica Ld |
| Allergan, INC. | $89.69 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $82.91 | 2019-2025 | Cabtreo |
| Journey Medical Corporation | $78.82 | 2024-2025 | |
| Verrica Pharmaceuticals INC. | $65.88 | 2024 | Ycanth |
| E.R. Squibb & Sons, L.L.C. | $63.24 | 2022-2023 | Sotyktu |
| Genentech USA, INC. | $48.44 | 2022-2024 | Xolair |
| Almirall LLC | $46.85 | 2020-2023 | Seysara |
| Epi Health, LLC | $38.91 | 2020 | |
| Organon LLC | $30.41 | 2025 | Vtama |
| Novum Pharma, LLC | $29.62 | 2019 | |
| Sanofi Pasteur INC. | $25.46 | 2024 | |
| Mimedx Group, INC. | $23.58 | 2025 | |
| Fidia Pharma USA INC. | $22.94 | 2025 | |
| Vyne Pharmaceuticals INC. | $21.68 | 2020 | |
| Mylan Pharmaceuticals INC. | $21.16 | 2019 | |
| Encore Dermatology INC. | $19.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lilly-Rose Paraskevas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.